Core Viewpoint - Seaport Research initiated coverage of Birkenstock with a Neutral rating, indicating concerns over slowing Google search interest growth year-over-year and a significant decline in U.S. search interest for the Boston model during the holiday season [1] Group 1: Company Initiations - Seaport Research initiated coverage of Birkenstock (BIRK) with a Neutral rating and no price target, citing slowing search interest [1] - Freedom Capital initiated coverage of Unity (U) with a Buy rating and a price target of $52, highlighting promising early traction for Unity's Vector AI technology and a valuation multiple under half that of AppLovin [1] - Freedom Capital initiated coverage of Phinia (PHIN) with a Buy rating and a price target of $82, noting its role as a global supplier benefiting from recurring replacement demand and cyclical exposure to vehicle production [1] - Morgan Stanley resumed coverage of Staar Surgical (STAA) with an Underweight rating and a price target of $13, following the termination of its merger agreement with Alcon, expressing concerns over the niche market for EVO ICL technology [1] - B. Riley initiated coverage of Knife River (KNF) with a Buy rating and a price target of $92, suggesting the stock is mispriced after recent underperformance compared to peers [1]

Core Insights - Alcon Inc. is a significant player in the ophthalmic industry, focusing on eye care products and surgical equipment, competing with major companies like Johnson & Johnson Vision and Bausch + Lomb [1] - Stifel Nicolaus has set a price target of $80 for Alcon, with the stock currently trading at $80.62, reflecting a slight decrease of approximately 0.77% from the target price [1][6] Company Developments - Alcon has terminated its agreement to acquire STAAR Surgical due to the failure to secure necessary stockholder votes, which may impact its market position and future growth strategies [2][6] - STAAR Surgical will continue as an independent publicly traded company, with a focus on profitable sales growth and enhancing distribution efficiencies, particularly expanding the use of its EVO ICL technology globally [3][6] Market Performance - Alcon's stock is currently priced at $80.62, showing a decrease of 0.49% or $0.40, with fluctuations between $79.68 and $81.11 today, and a 52-week high of $99.20 and a low of $71.55 [5] - Alcon's market capitalization is approximately $39.87 billion, with a trading volume of 1,128,034 shares [5]

Group 1 - STAAR Surgical Company did not receive the necessary stockholder votes to approve the merger agreement with Alcon Inc. and intends to terminate the agreement, remaining a standalone publicly traded company [1] - Broadwood Partners, which owns a 30.2% stake in STAAR, opposed the proposed sale and emphasized the company's strong financial position and growth potential [2] - Yunqi Capital Limited, holding a 5.1% stake in STAAR, also issued a letter opposing the merger deal [3] Group 2 - Alcon initially agreed to acquire STAAR for a total equity value of approximately $1.5 billion, later amending the terms to $30.75 per share, raising the total equity value to approximately $1.6 billion [3][4] - Following the news, STAAR Surgical shares fell by 12.20% to $21.02, while Alcon shares increased by 1.20% to $81.62 [4]